

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Bioceuticals Corp.
1000 - 355 Burrard Street
Vancouver, BC V6C 2G8

Item 2. Date of Material Change

August 8, 2014

Item 3. News Release

A news release dated and disseminated August 8, 2014 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

Item 4. Summary of Material Change

Abattis' appoints Jason Anderson as VP of finance.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Rene David, CFO
Telephone: 604.538.6650

Item 9. Date of Report

August 14, 2014

ABATTIS' APPOINTS JASON ANDERSON AS VP OF FINANCE

Vancouver, BC – August 8, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services to medicinal markets in North American, today announced the appointment of Jason Anderson, CA, CFA as Vice President of Finance.

"With over 20 years of experience in corporate finance, including 15 years experience on Wall Street and in international markets, Mr. Anderson will be an integral part of our corporate finance team as we continue to build momentum and pursue new opportunities," said Abattis Bioceuticals Corp. CEO Mike Withrow.

Mr. Anderson graduated from Stanford University with a B.A. in International Relations in 1988, was awarded the Chartered Financial Analyst ("CFA") Charter in 1995, received a Diploma in Accounting at the University of British Columbia in 2010, and was awarded the designation of Charter Public Accountant ("CPA") in 2013. Throughout his career, Mr. Anderson worked in both research and accounting positions with major companies like KPMG LLP and through his own practice.

Further, in compliance with the Company's option plan, the Company has granted 605,000 incentive stock options to certain of its directors and consultants, with each option being exercisable into a common share of Abattis at \$0.48 per share for a period of five years.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Mike Withrow"

Michael Withrow, President & CEO

For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-

Suite 1040 – 885 West Georgia Street,
Vancouver, BC V6C 3H1
Tel: 778-896-6536
Email: news@abattis.com



looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.